By Fineline Cube Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for its self-developed BJ044 injection (recombinant ulinastatin), produced via synthetic biology, potentially positioning it as the world’s first recombinant ulinastatin developed through this advanced manufacturing approach.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | Investigational New Drug (IND) application |
| Product | BJ044 injection (recombinant ulinastatin) |
| Development Platform | Synthetic biology manufacturing |
| Approval Date | June 30, 2026 |
| Strategic Significance | Potentially first globally to develop recombinant ulinastatin via synthetic biology |
Drug Profile: BJ044 (Recombinant Ulinastatin)
- Active Ingredient: Recombinant ulinastatin (bikunin)
- Molecular Nature: Glycoprotein with potent inhibitory activity
- Historical Discovery: First identified in human urine in 1909
- Manufacturing Innovation: Produced through proprietary synthetic biology platform
- Therapeutic Class: Multi-functional enzyme inhibitor with anti-inflammatory properties
Ulinastatin represents a unique therapeutic agent with broad-spectrum activity against multiple pathological processes. Its mechanism of action involves inhibition of various proteolytic enzymes—including trypsin, chymotrypsin, elastase, and hyaluronidase—while simultaneously modulating inflammatory cytokine production and protecting endothelial barrier function.
Clinical Applications & Market Opportunity
| Primary Indications | Secondary/Expanded Indications |
|---|---|
| Acute pancreatitis | Sepsis |
| Acute exacerbation of chronic relapsing pancreatitis | Severe pneumonia |
| Acute circulatory failure | Acute respiratory distress syndrome (ARDS) |
| Acute poisoning | |
| Severe heatstroke | |
| Burns | |
| Severe trauma |
The potential clinical utility of BJ044 spans critical care medicine, where multi-organ dysfunction and uncontrolled inflammation represent leading causes of mortality. Current ulinastatin products are derived from human urine extraction, creating supply constraints, batch-to-batch variability, and potential safety concerns. Shanghai Bao’s synthetic biology approach addresses these limitations by enabling consistent, scalable, and contamination-free production of recombinant ulinastatin.
Strategic Implications
| Aspect | Impact |
|---|---|
| Manufacturing Advantage | Synthetic biology enables unlimited scale-up vs. urine-derived supply constraints |
| Quality Consistency | Recombinant production eliminates batch variability inherent in biological extraction |
| Safety Profile | Eliminates risk of human pathogen contamination associated with urine-derived products |
| Market Leadership | Potential first-mover advantage in recombinant ulinastatin globally |
| Commercial Opportunity | Addresses substantial unmet need in critical care settings across China and internationally |
China’s critical care market represents a significant opportunity, with an estimated 2 million annual cases requiring intensive care unit admission. The ability to provide consistent, high-quality ulinastatin therapy could substantially improve outcomes in conditions like sepsis (mortality rate 30-50%) and ARDS (mortality rate 35-45%).
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential of BJ044. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech